Loading…
Loading…
Sarepta Therapeutics Investigation Initiated: Kahn Swick and Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRP
NEW YORK CITY and NEW ORLEANS, Sept. 4, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Canada Pension Plan Investment Board purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 70,800 shares of the biotechnology company's stock, valued at approximately $1,272,000. Canada Pension Plan
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 8:30 a.m. ET. The presentation will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and will be archived there f.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (“Sarepta” or the “Company”).Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy.
Bank of America Corp DE increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 26.6% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,145,926 shares of the biotechnology company's stock after buying an additional 450,336 shares during the
SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.